Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment

To be considered for this study, you must have completed a previous study for Benralizumab and your study doctor must agree that the treatment is still helping you. You also need to agree to use contraception methods as discussed with the study team, if that applies to you, for the duration of the study and for 12 weeks after your last dose. Importantly, you should not be able to get Benralizumab through your regular doctors or pharmacies right now, but your doctor believes you still need it.

There are also some reasons why you might not be able to join. For example, if you had a serious health problem at the end of your previous study that would make it unsafe to restart Benralizumab. You also cannot plan to have certain types of vaccines (live vaccines) or use other specific biological medicines while in this study, unless there's no other treatment for a health issue. Finally, if you're currently in another clinical study (apart from the original Benralizumab study) or if you left your first study early before completing the main treatment period, you wouldn't be able to join this one.

If you join this study, you would continue to receive the Benralizumab treatment that helped you in the previous trial. Your study doctor and nurses would regularly check on your health and the effects of the medicine. This involves scheduled visits where they might take blood samples, ask about your symptoms, and generally monitor how you are doing. The study is 'open-label', meaning both you and your doctor will know you are receiving Benralizumab. It's designed to make sure you keep getting treatment if it's working, so the duration will depend on your individual needs and how long the medicine continues to benefit you, or until the study itself ends.